Tax withholding sale by Twist Bioscience (TWST) SVP Paula Green

Rhea-AI Filing Summary

Twist Bioscience Corp executive Paula Green, SVP of Human Resources, reported an open-market sale of 1,465 shares of common stock at an average price of $46.7098 per share on February 23, 2026. According to the filing, these shares were sold to cover tax withholding obligations triggered by the vesting of Restricted Stock Units under the company’s equity incentive plans, and the sale was mandated as a “sell to cover” transaction rather than a discretionary trade. After this tax-related sale, she beneficially owns 125,336 shares, which include shares acquired through the company’s Employee Stock Purchase Plan in transactions exempt under Rule 16b-3(d) and Rule 16b-3(c).

Insider Trade Summary

Net Seller: 1,465 shares ($68,430)

Net Sell 1 txn

Insider Green Paula

Role SVP of Human Resources

Sold 1,465 shs ($68K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,465	$46.7098	$68K

Holdings After Transaction: Common Stock — 125,336 shares (Direct)

Footnotes (1)

1. Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Includes shares that were acquired under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Green Paula

(Last) (First) (Middle)

C/O TWIST BIOSCIENCE CORPORATION

681 GATEWAY BLVD.

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Twist Bioscience Corp [ TWST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP of Human Resources

3. Date of Earliest Transaction (Month/Day/Year)
02/23/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/23/2026		S		1,465(1)	D	$46.7098	125,336(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.

2. Includes shares that were acquired under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).

Remarks:

	/s/ Kendra Fox, as Attorney-in-Fact for Paula Green	02/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Twist Bioscience (TWST) report for Paula Green?

Twist Bioscience reported that SVP of Human Resources Paula Green sold 1,465 shares of common stock. The shares were sold at an average price of $46.7098 per share on February 23, 2026 to cover tax withholding obligations from Restricted Stock Unit vesting.

Was Paula Green’s Twist Bioscience (TWST) share sale a discretionary trade?

The sale was not a discretionary trade by Paula Green. The filing states the 1,465 shares were sold under a mandated “sell to cover” arrangement to satisfy tax withholding obligations related to Restricted Stock Unit vesting under Twist Bioscience’s equity incentive plans.

How many Twist Bioscience (TWST) shares does Paula Green own after this transaction?

After the tax-related sale, Paula Green beneficially owns 125,336 shares of Twist Bioscience common stock. This figure includes shares that were previously acquired under the company’s Employee Stock Purchase Plan in transactions exempt under Rule 16b-3(d) and Rule 16b-3(c).

What price per share was received in Paula Green’s Twist Bioscience (TWST) sale?

The reported average sale price was $46.7098 per Twist Bioscience share. This price applies to the 1,465 shares sold on February 23, 2026 in an open-market transaction executed specifically to cover tax withholding obligations tied to Restricted Stock Unit vesting.

Why did Twist Bioscience’s SVP sell shares in this Form 4 filing?

The shares were sold to fund tax withholding obligations from vesting Restricted Stock Units. Twist Bioscience’s equity incentive plans require a “sell to cover” transaction, so the 1,465-share sale reflects this plan election rather than a voluntary decision to reduce holdings.

Do Paula Green’s remaining Twist Bioscience (TWST) shares include ESPP purchases?

Yes. The filing notes that the 125,336 shares beneficially owned after the sale include shares acquired under Twist Bioscience’s Employee Stock Purchase Plan. These ESPP acquisitions were exempt transactions under both Rule 16b-3(d) and Rule 16b-3(c) of the securities regulations.